Nucleic acid therapies: Towards cardiac-specific recombinant adeno-associated viruses (rAAVs) of human origin: Directed evolution and characterization of novel AAV variants isolated from human failing hearts in models with human relevance and relevance fo
| Institution | Universität Heidelberg |
|---|---|
| Project leader | Patrick Most |
| Site | Heidelberg/Mannheim |
| Project type | Innovation Cluster |
| Funding | € 607.835,00 |
| Begin | 01.01.2021 |
| End | 31.12.2024 |
| Partnerprojekte |
|
Förderkennzeichen
81X2500195
Projektnummer
1326